Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus escitalopram (10 to 20mg/day). Twelve-week treatment plus double-blind extension for 12 weeks.
Phase of Trial: Phase III
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Agomelatine (Primary) ; Escitalopram
- Indications Major depressive disorder; Sleep disorders
- Focus Therapeutic Use
- Sponsors IRIS
- 03 Jul 2013 Results published in the International Journal of Neuropsychopharmacology.
- 13 Aug 2007 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History